Download PDF
Thromb Haemost 1987; 58(02): 709-713
DOI: 10.1055/s-0038-1645960
Original Article
Schattauer GmbH Stuttgart

Plasma Kallikrein-Kinin System in Patients with Uncomplicated Sepsis and Septic Shock-Comparison with Cardiogenic Shock

F Martínez-Brotóns
*   The Department of Hematology, Hospital de Bellvitge, Barcelona, Spain
,
J R Oncins
**   Intensive Care Unit, Hospital de Bellvitge, Barcelona, Spain
,
J Mestres
**   Intensive Care Unit, Hospital de Bellvitge, Barcelona, Spain
,
V Amargós
**   Intensive Care Unit, Hospital de Bellvitge, Barcelona, Spain
,
C Reynaldo
*   The Department of Hematology, Hospital de Bellvitge, Barcelona, Spain
› Author Affiliations
Further Information

Publication History

Received 07 January 1987

Accepted after revision 24 March 1987

Publication Date:
23 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Alterations of the kallikrein-kinin system consistent with activation and increased consumption have been re2ported in septic patients and it has been suggested that this activation could contribute to the development of septic shock.

The aim of this work was to confirm these alterations in septic patients and to investigate the possible existence of similar changes in subjects developing cardiogenic shock secondary to myocardial infarction as a model of non septic shock.

Patients with septic shock, especially in fatal cases, showed a highly significant decrease in levels of factor XII, prekallikrein, high molecular weight kininogen (HMW-kininogen), α2-macro-globulin (α2-M) and antithrombin III (AT-III). C1-esterase inhibitor (C1-INH) activity was increased in uncomplicated sepsis but came back to normal or was slightly decreased in septic shock.

Components and inhibitors of the kallikrein-kinin system were within normal limits in patients with cardiogenic shock.

Our findings support the idea of a contribution of the kallikrein-kinin system to the development of septic shock though this system does not seem to play a significant role in the pathogenesis of cardiogenic shock or seem to be altered as a consequence of it.

Key words

Factor XII - Kallikrein - Septicemia - Septic shock - Cardiogenic shock
 

  • References

  • 1 Mason DT, Melmon KL. Effects of bradykinin on forearm venous tone and vascular resistance in man. Cir Res 1965; 17: 106-113
    CrossrefPubMedGoogle Scholar
  • 2 Rocha e Silva M. The kinin trail: Possible significance of bradykinin and related kinins to autopharmacology. In: Pharmacology and the future of man. vol 5 Maxwell RA, Acheson G. (eds) Karger; Basel: 1972: 250-266
    Google Scholar
  • 3 de Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M. Inactivation of factor XII active fragment in normal plasma. Predominant role of Cl-inhibitor. J Clin Invest 1984; 73: 1542-1549
    CrossrefPubMedGoogle Scholar
  • 4 Schapira M, Scott CF, Colman RW. Contribution of Plasma Protease Inhibitors to the Inactivation of Kallikrein in Plasma. J Clin Invest 1982; 69: 462-468
    CrossrefPubMedGoogle Scholar
  • 5 Van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71: 149-158
    CrossrefPubMedGoogle Scholar
  • 6 Pixley RA, Schapira M, Colman RW. The regulation of human factor Xlla by plasma proteinase. J Biol Chem 1985; 260: 1723-1729
    PubMedGoogle Scholar
  • 7 Mason JW, Kleeberg U, Doland P, Colman RW. Plasma kallikrein and Hageman factor in gram negative bacteremia. Ann Intern Med 1970; 73: 545-551
    CrossrefPubMedGoogle Scholar
  • 8 Hirsch EF, Nakajima T, Oshima G, Erdos G, Herman CM. Kinin system responses in sepsis after trauma in man. J Surg Res 1974; 17: 147-153
    CrossrefPubMedGoogle Scholar
  • 9 O’Donnell TF, Clowes Jr GH, Taiamo RC, Colman RW. Kinin activation in the blood of patients with sepsis. Surg Gynecol Obstet 1976; 143: 539-543
    PubMedGoogle Scholar
  • 10 Gallimore MJ, Aasen AO, Lyngaas K HN, Larsbraaten M, Amundsen E. Falls in plasma levels of prekallikrein, high molecular weight kininogen and kallikrein inhibitors during lethal endotoxin shock in dogs. Thromb Res 1978; 12: 307-318
    CrossrefPubMedGoogle Scholar
  • 11 Aasen AO, Smith-Erichsent N, Gallimore MJ, Amundsen E. Studies on Components of the plasma Kallikrein-kinin system in plasma samples from normal individues and patients with septic shock. Adv Shock Res 1980; 4: 1-10
    PubMedGoogle Scholar
  • 12 Kalter ES, Daha MR, ten Cate JW, Verhoef J, Bouma BN. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985; 151: 1019-1027
    CrossrefPubMedGoogle Scholar
  • 13 Morrison DC, Cochrane CG. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J Exp Med 1974; 140: 797-811
    CrossrefPubMedGoogle Scholar
  • 14 Mason JW, Colman RW. The role of Hageman factor in disseminated intravascular coagulation induced by septicemia, neoplasia or liver disease. Thromb Diath Haemorrh 1971; 26: 325-331
    PubMedGoogle Scholar
  • 15 Hellgren M, Egberg N, Eklund J. Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients. Intensive Care Med 1984; 10: 23-28
    PubMedGoogle Scholar
  • 16 Laemmle B, Tran TH, Ritz R, Duckert F. Plasma prekallikrein, factor XII, antithrombin III, Cl-inhibitor and a2-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). Am J Clin Pathol 1984; 82: 396-404
    CrossrefPubMedGoogle Scholar
  • 17 Modig J. Experimental and clinical studies on adult respiratory distress syndrome. Acta Chir Scand 1985; Suppl 522: 215-229
    PubMedGoogle Scholar
  • 18 Velasco F, Torres A, Guerrero A, Andres P, Guerrero R, Aljama P, Alvarez F. Behaviour of the contact phase of blood coagulation in the adult respiratory distress syndrome (ARDS). Thromb Haemostas 1986; 55: 357-360
    PubMedGoogle Scholar
  • 19 Lasson A, Ohlsson K. Changes in the kallikrein kinin system during acute pancreatitis in man. Throm Res 1984; 35: 27-41
    CrossrefPubMedGoogle Scholar
  • 20 Greenberger PA. Contrast media reactions. J Allergy Clin Immunol 1984; 74: 600-605
    CrossrefPubMedGoogle Scholar
  • 21 Kierulf P, Aasen AO, Aune S, Godal HC, Ruud TE, Vaage J. Chromogenic peptide substrate assays in patients with multiple trauma. Acta Chir scand 1982; Suppl 509: 69-72
    PubMedGoogle Scholar
  • 22 Aasen AO. The proenzyme functional inhibition index. A new parameter for evaluation of severely injured and septic patient. Acta Chir Scand 1984; Suppl 522: 211-230
    PubMedGoogle Scholar
  • 23 Kalter ES, Vlooswijk R AA, Bouma BN. Determination of prekallikrein using an amidolytic assay in plasma samples of critically ill patients. Acta Chir Scand 1982; Suppl 509: 43-47
    PubMedGoogle Scholar
  • 24 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiences. Am J Clin Path 1961; 36: 212-219
    CrossrefPubMedGoogle Scholar
  • 25 Gallimore MJ, Friberg P. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein “like” activity in human plasma. Thromb Res 1982; 25: 293-298
    CrossrefPubMedGoogle Scholar
  • 26 Amundsen E, Gallimore MJ, Aasen AO, Larsbraaten M, Lyngaas K. Activation of human plasma prekallikrein: Influence of activators, activation time and temperature and inhibitors. Thromb Res 1978; 13: 625-636
    CrossrefPubMedGoogle Scholar
  • 27 Gallimore MJ, Aurell L, Friberger P, Gustavsson S, Rees WA. Chromogenic peptide substrate assays for determining functional activities of a2-macroglobulin and arantitrypsin using a new trypsin substrate. Thromb Haemostas 1983; 50: 230 (Abstr)
    PubMedGoogle Scholar
  • 28 Ødegard OR. Evaluation of an amidolytic heparin cofactor assay method. Thromb Res 1975; 7: 351-360
    CrossrefPubMedGoogle Scholar
  • 29 Kalter ES, van Dijk WC, Timmerman A, Verhoef J, Bouma BN. Activation of purified human plasma prekallikrein triggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis 1983; 148: 682-691
    CrossrefPubMedGoogle Scholar
  • 30 Klemperer MR, Rosen FS, Donaldson VH. A polypeptide derived from the second component of human complement (C’2) which increases vascular permeability. J Clin Invest 1969; 48: 44a-45a
    PubMedGoogle Scholar
  • 31 Aasen OA, Amundsen E. Aspects of proteolysis in lethal canine endotoxin shock. Scand J Surg 1982; Suppl 509: 23-31
    PubMedGoogle Scholar
  • 32 Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M, Cohen AB, Colman RW. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983; 72: 1672-1677
    CrossrefPubMedGoogle Scholar
  • 33 Colman RW, Edelman R, Scott CF, Gilman RH. Plasma kallikrein activation and inhibition during typhoid fever. J Clin Invest 1978; 61: 287-296
    CrossrefPubMedGoogle Scholar
  • 34 Donaldson VH. Serum inhibitor of C-l-esterase in health and disease. J Lab clin Med 1966; 68: 369-382
    PubMedGoogle Scholar
  • 35 Groenewald JH, Michell WL, Buchmann C. Preliminary report on an endotoxic trial. Proceedings of the 4th world congress on intensive and critical care medicine. Jerusalem 1985; 5 (Abstr)
    PubMedGoogle Scholar
  • 36 Triantaphyllopoulus DC, Cho MS. Effect of injection of Cl inactivator on the platelet count and blood coagulation in rabbits infused with endotoxin. Thromb Haemostas 1986; 55: 293
    PubMedGoogle Scholar
  • 37 Riebeck M, Philapitsch A, Wiesinger H, Welter HF. The role of Cl-esterase inhibitor during early septicemia. Proceedings of the Vllth international congress of emergency surgery. Munich. 1985
    PubMedGoogle Scholar
  • 38 Triantaphyllopoulus DC. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb Haemostas 1984; 51: 232-235
    PubMedGoogle Scholar
  • 39 Everett MM, Emerson TE. Antithrombin III (AT III) increases survival time and decreases mortality during endotoxin shock in the rat. Circul Shock 1984; 13 Abstr 29
    PubMedGoogle Scholar